Gene/Protein Disease Symptom Drug Enzyme Compound
Pivot Concepts:   Target Concepts:
Query: UMLS:C0023241 (Legionella)
 6,990 document(s) hit in 31,850,051 MEDLINE articles (0.00 seconds)

Thirty-two patients were treated by ofloxacin on bacteriological documented infections. They were Enterobacterias: n = 15 (MIC less than or equal to 0.06 to 0.5 microgram/ml); Pseudomonas aeruginosa and Acinetobacter: n = 1 (MIC 0.5 and 4 micrograms/ml); Staphylococcus: n = 6 (MIC less than or equal to 0.06 to 4 micrograms/ml); Pneumococcus: n = 1; Mycoplasma: n = 1; Chlamydia psittaci: n = 2; Legionella pneumophila: n = 1; Rickettsias: n = 4 (three mediterranean fevers one query fever). Ofloxacin was given orally from 400 to 800 mg per day (5 to 15 mg/kg/day). It was used alone 26 times and on 6 occasions it was associated with rifampin on 6 staphylococcal infections. On 19 cases it was used after failure or intolerance of initial therapy. Thirty times it was the first antibiotic substance used. Results were good mainly: 1) on nine pneumonitis (enterobacterias: 4; Pneumococcus: 1; Mycoplasma: 1; Chlamydia: 2; Legionella: 1) during a mean duration of twenty days; 2) urinary infections (n:7) provoked by E. coli and Enterobacter cloacae (mean duration: 20 days); 3) 4 osteo-articular-infections (mean duration: 77 days); 4) Rickettsial infections (n:4) during a mean duration of 11 days. Results are particularly noteworthy because patients treated had severe infections: 12 bacteremias, 1 endocarditis and 1 purulent meningitis. None severe adverse effect was observed.
 ...
PMID:[Ofloxacin (RU 43280). Clinical study]. 330 73

This paper reports the results of an open study to assess the efficacy (433 patients) and tolerance (453 patients) of spiramycin adipate given by slow intravenous infusion to treat severe acute bronchopulmonary infections in adults. Efficacy was good in 80.4% of patients. More specifically, high efficacy was obtained in 76.5% of 85 pneumococcal respiratory infections, 72% of 50 Haemophilus influenzae and H. parainfluenzae infections, 100% of 18 Mycoplasma infections, 100% of 16 Chlamydia infections and 93% of 14 Legionella infections. Tolerance was good in 83.5% of patients, moderate in 15.4% and poor in 6%. Venous irritation was the most frequent complication, observed in 16.3% of patients. No serious complication or sequel was observed. The authors conclude that spiramycin adipate constitutes an appropriate first-line treatment of acute bronchial and/or pulmonary infections in adults. While inferior to benzylpenicillin against Mycoplasma, Chlamydia and Legionella, spiramycin is as active as, and better tolerated than, erythromycin.
 ...
PMID:Acute bronchopulmonary infections: treatment with i.v. spiramycin. 330 47

Bronchopulmonary infections continue to be the major determinant of morbidity and mortality in patients with cystic fibrosis (CF). The basic pathogenesis of disease includes abnormal secretions and impaired mucociliary clearance. Colonization of the tracheobronchial tract with bacteria is then associated with a cycle of infection, inflammation and airway obstruction eventually leading to respiratory insufficiency. Early clinical features include persistent cough and failure to thrive. Hyperinflation and bronchial thickening are early radiographic changes suggestive of CF. Staphylococcus aureus is commonly the initial respiratory pathogen. Subsequently, Hemophilus influenzae and Pseudomonas aeruginosa colonize the respiratory tract. In addition, respiratory viruses and other pathogens such as Legionella and mycoplasma are implicated in the etiology of pulmonary infections. The culture of respiratory secretions such as sputum are important guidelines to the etiology of pulmonary infection in CF. The laboratory must be aware of the pathogens that are typical of this disease and use appropriate techniques and media. In large part, advances in treatment in CF over the past two decades are due to the availability of increasingly potent antibiotic agents. However, effective treatment must be multifaceted and include a variety of nonantimicrobial therapies. Different approaches to the antibiotic therapy of pulmonary infection in CF, including prevention, suppression, and definitive treatment are discussed. In addition to traditional antibiotic therapy, a variety of newer methods of therapy in CF are discussed. These include oral antipseudomonal antibiotics, corticosteroid therapy, aerosolized antibiotics, and continuous antimicrobial prophylaxis.
 ...
PMID:Pulmonary infections in children with cystic fibrosis. 331 17

Infections of the respiratory tract are among the most common causes for antibiotic prescribing. Their diagnosis within the community is generally limited to clinical criteria, and microbiological information is frequently lacking. Hospitalised patients with respiratory tract infections are more likely to undergo diagnostic sampling, but difficulties remain in reliably defining a microbial aetiology, thereby providing a confident basis for antibiotic selection. In considering the role of the cephalosporins in the treatment of respiratory tract infections, over 500 published articles have been reviewed. The pharmacokinetic considerations are discussed and the limitations of existing methodology are emphasised. Individual agents are reviewed by site of sepsis and conclusions are drawn from both comparative and non-comparative studies and in relation to currently recommended regimens. Although oral cephalosporins are widely used to treat upper respiratory tract infections, none is considered ideal, especially where Haemophilus influenzae is pathogenic. In the case of lower respiratory tract infections the beta-lactamase stable parenteral cephalosporins have become widely used to treat pneumonia in hospitalised patients, especially where Gram-negative enteric bacilli are of aetiological importance. However, the lack of activity of these drugs against Legionella spp., Mycoplasma pneumoniae and Coxiella burnetii must be emphasised. Another area of increasing use is in the treatment of infective exacerbations in patients suffering from cystic fibrosis of the lungs where Pseudomonas aeruginosa is pathogenic; ceftazidime in particular has proved a useful alternative to earlier antipseudomonal penicillin antibiotics.
 ...
PMID:Treatment of respiratory tract infections with cephalosporin antibiotics. 331 1

The activity of roxithromycin against Legionella pneumophila in vitro was approximately the same as that of rokitamycin and superior to those of erythromycin and josamycin. In experimental pneumonia due to L. pneumophila none of the animals in the roxithromycin and rifampicin groups died by day 10 of the infection. The MIC ranges of roxithromycin, erythromycin and rokitamycin for Mycoplasma pneumoniae were 0.008-0.063, 0.004-0.008 and 0.016-greater than 125, respectively. In experimental pneumonia caused by M. pneumoniae, roxithromycin showed good activity similar to that of erythromycin.
 ...
PMID:Activity of macrolides against organisms responsible for respiratory infection with emphasis on Mycoplasma and Legionella. 342 89

General screening investigations with various antigens were carried out with a view to further specific investigations being carried out on the Cape Verde Islands concerning infectious diseases. Serological positive reactions were found in Mumps, Adeno, PLT, Cytomegaly, Herpes, Para-influenza 1, 2, 3, Influenza A and B, Mycoplasmosis, RS-Virus, Gonorrhoea, Hepatitis A and B, R. conori, Malaria, Syphilis, Brucella abortus, Brucella melitensis, Varicella, Legionella, Picornavirus, Measles, German Measles, Listeriosis, Toxoplasmosis and Amoebic dysentery.
 ...
PMID:Serological screenings of various infectious diseases on the Cape Verde Islands (West Africa). 344 44

In serological investigations undertaken in two hospitals in Nigeria a total of 188 blood samples were examined and the following positive reactions for various diseases found: malaria 100%, leishmaniasis 9.5%, biharziasis 2.1%, yersinia 16.4%, Legionella pn. 9%, gonorrhea 6%, syphilis 6.9%, measles 65.4%, rubella 84%, cytomegalic 78.2%, herpes simplex 67%, varicella 30.8%, Resp. sync. virus 34.6%, influenza A 57.4%, influenza B 73.9%, para-influenza 1, 2, 3, 20.7%, 16.5%, 52.6%, adenovirus 25%, Mycoplasma pneumoniae 33.5%.
 ...
PMID:Serological testing of human blood samples for infectious diseases in the Abeokuta and the Minna Hospitals/Nigeria. 344 50

The penetration of ofloxacin into bronchial secretions was evaluated in 16 patients after administration of a single oral dose of ofloxacin 400mg. Bronchial secretions were aspirated at bronchoscopy after 1 to 6 hours and serum was collected simultaneously. Ofloxacin concentrations were measured by a microbiological assay method. Considerable individual variations in serum and bronchial aspirate concentrations were recorded: bronchial aspirate concentrations varied between 1.1 mg/L and 4.5 mg/L but exceeded 1.5 mg/L in 14 of 16 patients between 1 and 6 hours. The ratio between simultaneous mean bronchial aspirate and serum concentrations ranged between 0.53 in the second hour and 0.92 in the fourth hour. It is likely that inhibitory activity will be sustained over at least 6 hours against most potential respiratory pathogens including Haemophilus influenzae, Branhamella catarrhalis, Gram-negative bacilli, Staphylococcus aureus, Legionella pneumophila and Mycoplasma pneumoniae. Streptococcus pneumoniae and Pseudomonas aeruginosa may have minimal inhibitory concentration (MIC) values lower than ofloxacin concentrations achieved in bronchial secretions, although some isolates are less sensitive. Clinical studies should establish the relevance of pharmacokinetic data to respiratory infections caused by organisms of borderline susceptibility.
 ...
PMID:Penetration of ofloxacin into bronchial secretions. 348 25

The activity of roxithromycin was determined by a microdilution method, in comparison with erythromycin, spiramycin and josamycin. Roxithromycin and erythromycin showed very similar MICs against staphylococci, Streptococcus pneumoniae, Str. pyogenes and Haemophilus influenzae. In most cases, spiramycin and josamycin appeared similarly or more active. The activity of roxithromycin against Mycoplasma pneumoniae, Legionella spp., Chlamydia psittaci and, to some extent, against Pasteurella spp. was also assessed, by suitable in-vitro methods. Roxithromycin has a promising potential for treating selected skin and respiratory infections.
 ...
PMID:In-vitro activity of roxithromycin against respiratory and skin pathogens. 350 24

The sensitivity of the indirect immunofluorescence (IFA) test in Legionella pneumophila infection is said to be maximal when a plyimmunoglobulin conjugate is used. However commercially available non-class-specific fluorescent antisera are not always sensitive enough to detect IgM antibodies as class-specific conjugates do. IFA test's drawback is its inability to detect early stages of infection. We routinely performed the microagglutination (MA) test in order to check the reliability of this test alone in screening diagnostic work for L. pneumophila group 1 infections. The 252 sera tested were from suspected or confirmed legionellosis cases. Five-hundred and thirty sera from healthy-people, 49 sera from patients with serologically confirmed chlamydia, coxiella and mycoplasma pneumonia, and ten sera from patients with Pseudomonas aeruginosa infection were used as controls. There was a good agreement between IFA and MA tests, the MA proving almost as specific as, and in some cases more sensitive than the IFA test. This was particularly evident in early stages of infection. For these reasons, together with its low cost and the ease to perform, it appears that the MA test can be a useful screening test for presumptive cases of legionellosis even on a single serum specimen.
 ...
PMID:More experience on the microagglutination test in the diagnosis of Legionella pneumophila infection. 351 65


<< Previous 1 2 3 4 5 6 7 8 9 10 Next >>